Akhil Abraham Saji, MD

Akhil Abraham Saji, MD, is a urologist specializing in minimally invasive surgery and urologic oncology with an interest in technology-driven innovation within health care.

Articles by Akhil Abraham Saji, MD

Akhil Abraham Saji, MDUrothelial Carcinoma | March 1, 2024
NARUS served as a platform for surgeons to share insights into the advancements and future directions of robotic surgery.
Read More
Akhil Abraham Saji, MDProstate Cancer | January 3, 2024
Highlighting some of the primary advancements identified within urologic oncology during 2023 and what to anticipate in 2024.
Akhil Abraham Saji, MDMuscle Invasive Urothelial Carcinoma | December 28, 2023
A combination of current guidelines and RCTs give surgeons clarity on the benefit of extended PLND in bladder cancer.
Akhil Abraham Saji, MDRenal Cell Carcinoma | November 29, 2023
A review of some of the latest techniques and applications of the SP platform for kidney and upper urinary tract surgery.
Akhil Abraham Saji, MDSUO 2023 | November 27, 2023
The meeting covers a range of topics, including prostate cancer, kidney cancer, and bladder cancer, as well as penile cancer.
Akhil Abraham Saji, MDAdvanced Urothelial Carcinoma | November 1, 2023
This is the first trial that has shown an OS benefit improvement over chemo in the 1L mUC setting, a landmark achievement.
Akhil Abraham Saji, MDAdvanced Renal Cell Carcinoma | November 1, 2023
Surgery in advanced RCC has come into question and requires further clarification on when and how it should be utilized.
Akhil Abraham Saji, MDRLT | October 5, 2023
This review highlights some of the most exciting abstracts and presentations in GU oncology at the ESMO Congress 2023.
Akhil Abraham Saji, MDProstate Cancer | September 28, 2023
Patients considering PC screening should talk to their PCP or urologist about the benefits and risks of identifying PC early.
Akhil Abraham Saji, MDLocalized | November 29, 2023
The da Vinci Single Port platform allows robot-assisted surgical procedures with the same precision as multiport techniques.
Akhil Abraham Saji, MDProstate Cancer | September 20, 2023
Increasing competition in robot-assisted surgical platform production will increase accessibility for patients everywhere.
Akhil Abraham Saji, MDProstate Cancer Diagnostics | July 31, 2023
PSMA PET imaging is a leap forward in the fight to cure prostate cancer, especially as theranostic capabilities expand.
Akhil Abraham Saji, MDLocalized | July 31, 2023
What role can artificial intelligence play in the diagnosis and management of prostate cancer utilizing MRI?
Akhil Abraham Saji, MDAUA 2023 | May 31, 2023
One might assume that the AUA meeting is geared toward practicing urologists, but it is also crucial for urologic trainees.
Akhil Abraham Saji, MDLocalized | May 30, 2023
The postsurgical treatment of functional outcomes such as UI and ED after SRP remains a challenge for all urologists.
Akhil Abraham Saji, MDNon-Muscle Invasive Urothelial Carcinoma | June 8, 2023
FDA approval of Adstiladrin for use in BCG-unresponsive NMIBC expands the armamentarium for treatment of high-risk NMIBC.
David Ambinder, MDAUA 2023 | May 2, 2023
Drs. David Ambinder and Akhil Saji highlight the importance of attending the AUA meeting as urology residents.
Akhil Abraham Saji, MDNon-Muscle Invasive Urothelial Carcinoma | June 16, 2023
NMIBC-associated costs vary widely across types of treatments utilized, health systems, and regions of the country.
Akhil Abraham Saji, MDMuscle Invasive Urothelial Carcinoma | May 1, 2023
The minimally invasive options available to patients diagnosed with muscle-invasive disease of urothelial origin are limited.
Akhil Abraham Saji, MDProstate Cancer | March 31, 2023
This review highlights the existing research regarding the financial toxicity of advanced prostate cancer.